Companies like AG1, Ritual, and Blueland are investing in clinical research as a growth engine, not just to support existing claims, per Modern Retail.
ReadingThe steal: most brands cite clinical research after the fact—'our product was studied and here's the result.' AG1, Ritual, and Blueland are funding studies first, designing them to be newsworthy, and using the findings as launch announcements. This shifts them from 'trust our formula' to 'trust the science we paid for.' For a $5M+ supplement or wellness brand, commissioning a $100-300k clinical study is 2-4% of revenue and can unlock 3-5 years of credibility. The move: pick ONE claim (gut health, vitamin absorption, sustainability impact), fund a 12-week study with a credible third party, publish in a relevant journal, then spend the next two years selling against that research. Every testimonial becomes anecdotal evidence supporting the published study.
MY STASH TAKEClinical research used to be a luxury play. Now it's a survival play. The supplement space got crowded because anyone can make a greens powder and claim it works. The brands pulling ahead are the ones saying 'we paid researchers to prove it.' This is not new—pharma has been doing it for 50 years. But it's new in DTC. If you're in supplements, clean products, or wellness, a clinical study is not a nice-to-have; it's the moat. It's also the only thing competitors can't copy. They can copy your formula, your packaging, your influencers. They can't copy your published research.
WatchWatch for AG1 or Ritual to announce a new study in Q4 2026 and tie it to a product launch or reformulation.